stockrow
Monday 9 November 2026
Export ABEO’s income statement to Excel — free account
Abeona Therapeutics Inc.
ABEOAbeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023.
- Revenue
- +225.1%
- EPS
- −116.9%
- Free cash flow
- +17.1%
- Total debt
- −23.4%
Quarter to June 2026, against a year earlier
4.17
0.26
+6.65%
Follow ABEO
Alert me
Abeona Therapeutics Inc. (ABEO) P/E ratio
Abeona Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 7.2× (August 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 4.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 3.6× | (10.91%) |
| Dec 2025 | 4.0× | (28.50%) |
| Jun 2025 | 5.6× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 7.2×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACIU AC Immune compare | n/m |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| FATE Fate Therapeutics, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| ABEO Abeona Therapeutics Inc. | n/m |
| EVMN Evommune Inc. compare | n/m |
| IMRX Immuneering Corporation compare | n/m |
| KRRO Korro Bio, Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)